Evaluation of the Proportion of Hormonal and Progenotoxic Effects of Estrogens and Glucose in Cancer Patients

被引:0
作者
L. M. Berstein
T. E. Poroshina
D. A. Vasilyev
M. P. Boyarkina
机构
[1] Ministry of Health and Social Development,N. N. Petrov Institute of Oncology
来源
Bulletin of Experimental Biology and Medicine | 2010年 / 150卷
关键词
estrogens; glucose; hormonal and genotoxic effect;
D O I
暂无
中图分类号
学科分类号
摘要
The progenotoxic (G, generation of reactive oxygen forms in mononuclears) and hormonal (H, reactive insulinemia) effects of oral glucose, on the one hand, and the same effects of estradiol (10–8 and 10–5 M) in vitro on blood mononuclears (G: by comet tail length; H: by expression of AMP kinase and TNF and IL-6 secretion), on the other, were compared with consideration for the concepts on endocrine genotoxic switch-over in patients with breast cancer and endometrial cancer in remission. Coculturing of mononuclears with estradiol in general led to an increase in comet tail and was associated with a trend to more intense expression of AMP kinase and IL-6 secretion. The reaction to estradiol (primarily in a concentration of 10–8 M) evaluated by the expression of AMP kinase and TNF secretion was more intensive than the reaction evaluated by comet tail lengths or by percentage of cells with comets in women with predominating progenotoxic effect of glucose vs. hormonal effect. This fact can be used as a landmark in search for means for optimization of the status and proportion of effects in the estrogen and glucose systems.
引用
收藏
页码:243 / 246
页数:3
相关论文
共 35 条
[1]  
Vasil’yev DA(2008)undefined Uspekhi Gerontol. 21 204-211
[2]  
Poroshina TE(2001)undefined Shock 16 340-343
[3]  
Kovalenko IG(2006)undefined Horm. Metab. Res. 38 650-655
[4]  
Asai K(2006)undefined Ann. N. Y. Acad. Sci. 1089 286-301
[5]  
Hiki N(1998)undefined Metabolism 47 788-791
[6]  
Mimura Y(2008)undefined Obesity 16 1284-1288
[7]  
Berstein LM(2008)undefined Appl. Physiol. Nutr. Metab. 33 75-85
[8]  
Vasilyev DA(2003)undefined Environ. Mol. Mutagen 41 104-110
[9]  
Poroshina TE(2006)undefined J. Invest. Dermatol. 126 1036-1042
[10]  
Kovalenko IG(2007)undefined FASEB J. 21 746-747